آلوگلیپتین (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "آلوگلیپتین" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2^nd place

2^nd place

2web.archive.org

1^st place

1^st place

68^th place

179^th place

low place

low place

3,558^th place

4,625^th place

102^nd place

515^th place

1semanticscholar.org

11^th place

52^nd place

6^th place

9^th place

447^th place

382^nd place

aace.com (Global: low place; Persian: low place)

"www.aace.com" (PDF). Archived from the original (PDF) on 2018-11-01.

archive.org (Global: 6^th place; Persian: 9^th place)

White WB, Zannad F (January 2014). "Saxagliptin, alogliptin, and cardiovascular outcomes". N. Engl. J. Med. 370 (5): 483–484. doi:10.1056/NEJMc1313880. PMID 24482824.

doi.org (Global: 2^nd place; Persian: 2^nd place)

Saisho, Y (2015). "Alogliptin benzoate for management of type 2 diabetes". Vascular Health and Risk Management. 11: 229–43. doi:10.2147/VHRM.S68564. PMC 4401208. PMID 25914541.
White WB, Cannon CP, Heller SR, et al. (October 2013). "Alogliptin after acute coronary syndrome in patients with type 2 diabetes" (PDF). N. Engl. J. Med. 369 (14): 1327–35. doi:10.1056/NEJMoa1305889. hdl:10447/94479. PMID 23992602. S2CID 205095844.
White WB, Zannad F (January 2014). "Saxagliptin, alogliptin, and cardiovascular outcomes". N. Engl. J. Med. 370 (5): 483–484. doi:10.1056/NEJMc1313880. PMID 24482824.

europa.eu (Global: 68^th place; Persian: 179^th place)

ema.europa.eu

Vipidia: EPAR summary for the public بایگانی‌شده در ۱۹ ژوئن ۲۰۱۸ توسط Wayback Machine (European Medicines Agency)

fda.gov (Global: 447^th place; Persian: 382^nd place)

"DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 2015-08-28. Retrieved 1 September 2015.

handle.net (Global: 102^nd place; Persian: 515^th place)

hdl.handle.net

White WB, Cannon CP, Heller SR, et al. (October 2013). "Alogliptin after acute coronary syndrome in patients with type 2 diabetes" (PDF). N. Engl. J. Med. 369 (14): 1327–35. doi:10.1056/NEJMoa1305889. hdl:10447/94479. PMID 23992602. S2CID 205095844.

nih.gov (Global: 4^th place; Persian: 5^th place)

pubmed.ncbi.nlm.nih.gov

Saisho, Y (2015). "Alogliptin benzoate for management of type 2 diabetes". Vascular Health and Risk Management. 11: 229–43. doi:10.2147/VHRM.S68564. PMC 4401208. PMID 25914541.
White WB, Cannon CP, Heller SR, et al. (October 2013). "Alogliptin after acute coronary syndrome in patients with type 2 diabetes" (PDF). N. Engl. J. Med. 369 (14): 1327–35. doi:10.1056/NEJMoa1305889. hdl:10447/94479. PMID 23992602. S2CID 205095844.
White WB, Zannad F (January 2014). "Saxagliptin, alogliptin, and cardiovascular outcomes". N. Engl. J. Med. 370 (5): 483–484. doi:10.1056/NEJMc1313880. PMID 24482824.

ncbi.nlm.nih.gov

Saisho, Y (2015). "Alogliptin benzoate for management of type 2 diabetes". Vascular Health and Risk Management. 11: 229–43. doi:10.2147/VHRM.S68564. PMC 4401208. PMID 25914541.

semanticscholar.org (Global: 11^th place; Persian: 52^nd place)

api.semanticscholar.org

White WB, Cannon CP, Heller SR, et al. (October 2013). "Alogliptin after acute coronary syndrome in patients with type 2 diabetes" (PDF). N. Engl. J. Med. 369 (14): 1327–35. doi:10.1056/NEJMoa1305889. hdl:10447/94479. PMID 23992602. S2CID 205095844.

uq.edu.au (Global: 3,558^th place; Persian: 4,625^th place)

espace.library.uq.edu.au

White WB, Cannon CP, Heller SR, et al. (October 2013). "Alogliptin after acute coronary syndrome in patients with type 2 diabetes" (PDF). N. Engl. J. Med. 369 (14): 1327–35. doi:10.1056/NEJMoa1305889. hdl:10447/94479. PMID 23992602. S2CID 205095844.

web.archive.org (Global: 1^st place; Persian: 1^st place)

Vipidia: EPAR summary for the public بایگانی‌شده در ۱۹ ژوئن ۲۰۱۸ توسط Wayback Machine (European Medicines Agency)
"www.aace.com" (PDF). Archived from the original (PDF) on 2018-11-01.